ArticleInternational journal of inflammation2013
Targeting inflammation in emerging therapies for genetic retinal disease.
Article in International journal of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Targeting the CCL7-STAT1 axis attenuates microglial neurotoxicity and photoreceptor degeneration in retinitis pigmentosa.Journal of neuroinflammation · 2026Article
- Case Report: A case of unexplained retinoschisis.Frontiers in medicine · 2025Article
- Flavonoid supplements increase neurotrophin activity to modulate inflammation in retinal genetic diseases.Acta bio-medica : Atenei Parmensis · 2020Review
- Recent Research on the Health Benefits of Blueberries and Their Anthocyanins.Advances in nutrition (Bethesda, Md.) · 2020Review
- Lipopolysaccharide-Induced Autophagy Mediates Retinal Pigment Epithelium Cells Survival. Modulation by the Phospholipase D Pathway.Frontiers in cellular neuroscience · 2019Article
- Amelioration of Mouse Retinal Degeneration After Blue LED Exposure by Glycyrrhizic Acid-Mediated Inhibition of Inflammation.Frontiers in cellular neuroscience · 2019Article
- Alpha-1 Antitrypsin Attenuates M1 Microglia-Mediated Neuroinflammation in Retinal Degeneration.Frontiers in immunology · 2018Article
- Combined transplantation of human mesenchymal stem cells and human retinal progenitor cells into the subretinal space of RCS rats.Scientific reports · 2017Article
- TNFa knockdown in the retina promotes cone survival in a mouse model of autosomal dominant retinitis pigmentosa.Biochimica et biophysica acta. Molecular basis of disease · 2017Article
- The transcorneal electrical stimulation as a novel therapeutic strategy against retinal and optic neuropathy: a review of experimental and clinical trials.International journal of ophthalmology · 2016Review
- Anthocyanin can arrest the cone photoreceptor degeneration and act as a novel treatment for retinitis pigmentosa.International journal of ophthalmology · 2016Review
- Infliximab reduces Zaprinast-induced retinal degeneration in cultures of porcine retina.Journal of neuroinflammation · 2014Article
- Altered miRNA expression in canine retinas during normal development and in models of retinal degeneration.BMC genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic retinal diseases such as age-related macular degeneration and monogenic diseases such as retinitis pigmentosa account for some of the commonest causes of blindness in the developed world. Diverse genetic abnormalities and environmental causes have been implicated in triggering multiple pathological mechanisms such as oxidative stress, lipofuscin deposits, neovascularisation, and programmed cell death. In recent years, inflammation has also been highlighted although whether inflammatory mediators play a central role in pathogenesis or a more minor secondary role has yet to be established. Despite this, numerous interventional studies, particularly targeting the complement system, are underway with the promise of novel therapeutic strategies for these important blinding conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.